We were looking through the IPO class of 2012 and something incredible stood out. From the IPOs that came out this summer, there are eight IPOs which are actually up 50% or more. The list of post-IPO gainers was so strong that it was almost hard to believe.

The list of IPO winners includes the following now-public companies: Five Below, Inc. (NASDAQ: FIVE); Chuy’s Holdings, Inc. (NASDAQ: CHUY); ServiceNow Inc. (NYSE: NOW); Eloqua, Inc. (NASDAQ: ELOQ); Globus Medical, Inc. (NYSE: GMED); Northern Tier Energy LP (NYSE: NTI); Vitamin Cottage Natural Food Markets, Inc. (NYSE: NGVC); and Bloomin’ Brands, Inc. (NASDAQ: BLMN). We took a look at each to determine the value and to see what the interest. We also gave a consensus Thomson Reuters price target, although we would warn readers that these consensus figures are often not very relevant when companies are this new.

Five Below, Inc. (NASDAQ: FIVE) is now up over 125% from its July IPO. Shares even hit another post-IPO high on Monday. This is not quite a dollar store, but it is a $5 and under store geared toward the young consumer. The $17 IPO now has a new post-IPO range of $25.00 to $40.00. Analyst price target: $35.29

Chuy’s Holdings , Inc. (NASDAQ: CHUY) was up over 7% at $26.43 on Monday and that tipped shares above a 100% gain since its IPO. The Tex-Mex chain still has many new growth markets to target and its July IPO of $13 is now above $26.00. What is so peculiar about this IPO is that it often trades under 100,000 shares in a trading day. Analyst price target: $22.33

ServiceNow Inc. (NYSE: NOW) saw its stock lose about 10% on Monday after UBS downgraded the stock. This enterprise information technology management software-as-a-service provider is still a winner as the $34.70 price compares to its $18 IPO price from late June. The post-IPO range has been $22.62 to $41.77. Analyst price target: $31.88

Eloqua, Inc. (NASDAQ: ELOQ) is up 70% at $19.70 from its $11.50 IPO from the start of August. The volume had dwindled to a very low level here of under 100,000 shares but over the last two weeks it seems to have picked up as institutions likely bought shares up. The company has a SaaS model and provides on-demand revenue performance management software solutions for businesses. The market cap is $631 million. Analyst price target: $20.25

Globus Medical, Inc. (NYSE: GMED) was up at a new post-IPO high of $19.10 on Monday and this is up more than 55% from its $12 IPO in early August. The medical device company sells products that promote healing in patients with spine disorders and the market cap here is about $1.7 billion. The excitement seems tied to a recent approval of its SECURE®-C Cervical Artificial Disc. Analyst price target: $18.42

Northern Tier Energy LP (NYSE: NTI) has performed incredibly well. The MLP is up more than 50% after hitting a new post-IPO high of $21.50 on Monday. This one came public in late-July at $14 per unit and the 52-week range has bene $13.00 to $21.50. We are still waiting for its formal distribution to calculate a yield-equivalent here but the excitement has been obvious based on its price. Analyst price target: $22.67

Vitamin Cottage Natural Food Markets, Inc. (NYSE: NGVC) has been a stellar IPO for groceries, vitamins, and body care products. Its $15 IPO in late July is now up about 52% at $22.81 and its post-IPO range has been $17.20 to $23.30. The market cap here is still just under $500 million. Analyst price target: $24.33

Bloomin’ Brands, Inc. (NASDAQ: BLMN) hit a new high of $16.65 on Monday, which gives it a 51% jump over its $11 IPO from early August. This one owned and operated more than 1250 restaurant chains under the brands of Outback Steakhouse, Carrabba’s Italian Grill, Bonefish Grill, and Fleming’s Prime Steakhouse. This is a repackaged IPO after having been taken private under the old Outback Steakhouse corporate name. Apparently the public likes its value and the private equity sellers are sitting on that much more value now. Analyst price target: $17.31

JON C. OGG

AK Steel Holding Corp. (NYSE: AKS) cut to Sell at UBS.

Amphenol Corp. (NYSE: APH) cut to Neutral at BofA/ML.

ArcelorMittal (NYSE: MT) named as Bear of the Day at Zacks.

AutoNation Inc. (NYSE: AN) named as Bull of the Day at Zacks.

Chesapeake Energy Corp. (NYSE: CHK) maintained Hold at Argus.

GlaxoSmithKline (NYSE: GSK) cut to Neutral at UBS.

Globus Medical Inc. (NYSE: GMED) started as Buy at Goldman Sachs, started as Buy at Canaccord Genuity, started as Outperform at Oppenheimer and started as Buy at BofA/ML.

IAC/InterActiveCorp. (NASDAQ: IACI) reiterated Buy with $62 target at Canaccord Genuity.

Kenexa Corp. (NYSE: KNXA) cut to Neutral at Credit Suisse.

M&T Bank Corp. (NYSE: MTB) maintained Neutral but raised target to $102 from $96 at Credit Suisse.

Pharmacyclics Inc. (NASDAQ: PCYC) cut to Sector Perform at RBC.

VMware Inc. (NYSE: VMW) reiterated Buy with $120 price target at BofA/ML.

BofA/Merrill Lynch said that Nokia Corp. (NYSE: NOK) benefits from the Apple Inc. (NASDAQ: AAPL) litigation victory over Samsung are likely to be minor.

A firm named CLSA has started Ford Motor Co. (NYSE: F) with an Outperform rating and started General Motors Corp. (NYSE: GM) with an Underperform rating.

Argus has maintained a Buy rating on Dell Inc. (NASDAQ: DELL) with an $18 price target; Hewlett-Packard Co. (NYSE: HPQ) reiterated Buy but cut target to $25 from $30. The problem is that Argus calls Dell in a painful transition away from PCs and said difficulties persist at HP while a deep value story is there.

JON C. OGG

There is a huge underwriting group for the size of this offering.  Underwriters include BofA Merrill Lynch, Goldman Sachs, Piper Jaffray, Leerink Swann, Canaccord Genuity, William Blair & Company, and Oppenheimer & Co.

Globus is a medical device company focused exclusively on the design, development and commercialization of products that promote healing in patients with spine disorders. It noted, “We are an engineering-driven company with a history of rapidly developing and commercializing products that assist surgeons in effectively treating their patients, respond to evolving surgeon needs and address new treatment options.”

The company claims to have launched over 100 products since its inception in 2003.  The company has also grown its sales from $15.6 million in 2004 to $331.5 million in 2011.  For the year ended December 31, 2011, Globus had $118.6 million in Adjusted EBITDA, representing an Adjusted EBITDA margin of 36%, and $60.8 million of net income.

While this company is not widely known by the public, it is refreshing to see an IPO filing from a medical technology player that has both growing revenues and profits.

FULL IPO FILING

JON C. OGG